TACE Combined With Bevacizumab in HCC (BCLC-B) Beyond Up-To-Seven Criteria
Status:
Not yet recruiting
Trial end date:
2025-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy and safety of transcatheter arterial
chemoembolization (TACE) combined with anti-VEGF (Bevacizumab Biosimilar) in patients with
BCLC-B stage hepatocellular carcinoma beyond up-to-seven criteria.